This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
AACR 2023
Presentations
Brentuximab Vedotin | Solid Tumors | Poster #3253
CD30 is a marker of activated effector regulatory T cells in solid tumors providing clinical rationale for the combination of brentuximab vedotin and PD-1 inhibitors
Enfortumab Vedotin | Preclinical | Abstract #LB246
Enfortumab vedotin, a Nectin-4-directed antibody-drug conjugate, demonstrates compelling antitumor activity in non-muscle invasive bladder cancer models and accurately predicts minimal systemic exposure when administered by intravesical instillation in patients
Tisotumab Vedotin | SCCHN | Abstract #CT164
Tisotumab vedotin in squamous cell carcinoma of head and neck: interim analysis from innovaTV 207
Tucatinib | Breast Cancer | Abstract #CT065
Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial-in-progress)
Tucatinib | GI Cancer | Poster #5060
Tucatinib does not alter oxaliplatin PK or associated renal function: An OCT2/MATE transport inhibition study
Disitamab Vedotin | Abstract #560
Disitamab vedotin, an investigational HER2-directed antibody-drug conjugate, shows potent antitumor activity as a monotherapy and in combination with tucatinib in preclinical cancer models
SGN-BB228 | Poster #5676
SGN-BB228, a CD228-directed costimulatory antibody anticalin bispecific provides potent and conditional 4-1BB costimulation to T cells in vivo and in an in vitro model of T-cell exhaustion
SGN-B6A | Poster #1522
SGN-B6A induces immunogenic cell death as an additional mechanism of action
TLR7/8 | Poster #1542
Generation of an antibody-drug conjugate-optimized TLR7/8 agonist payload
SEA-TGT | Advanced Malignancies | Abstract #CT265
Phase 1 dose-escalation study of SEA-TGT monotherapy in patients with advanced malignancies (SGNTGT-001)
SEA-TGT | Abstract #5668
Using a clinical utility index (CUI) to determine the optimal biological dose of a nonfucosylated anti-TIGIT antibody: A proposed alternative to maximum tolerated dose (MTD)
SEA-TGT | Abstract #6361
A preclinical model of acquired anti-PD-1 resistance is responsive to SEA-TGT, an effector-function enhanced anti-TIGIT monoclonal antibody
Discovery Research | Poster #4890
A novel topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5 has potent antitumor activity in colorectal cancer models
Discovery Research | Poster #2013
Oxidized anthracycline payloads induce antitumor immunogenic cell death and show linker-dependent tolerability when delivered as ADCs
Discovery Research | Poster#2656
Reversible chemical modification of antibodies: A complementary approach to tuning FcγR binding that maintains antitumor activity while mitigating peripheral immune activation
Discovery Research | Poster #4892
MMAE drives immunomodulatory changes in a preclinical xenograft model that are distinct from other clinical-stage ADC payloads